Arthritis patients were left confused following the FDA action in April 2005 to withdraw Bextra from the market and add warnings and labeling changes to other NSAIDs. Many patients were left wondering if the drugs they had been taking to treat arthritis pain and inflammation were safe or if they needed to switch to another medication. What did the American College of Rheumatology and Arthritis Foundation think about the FDA action?

• Information For Patients Regarding COX-2 Selective NSAIDs (from ACR)
• Letter to FDA Regarding NSAIDs (from ACR)
• Straight Talk About Selective COX-2 Inhibitors and NSAIDs (from AF)

You can make your voice heard about how the FDA action has impacted you. Send your comments to the CDER (Center for Drug Evaluation and Research).

Related Resources:

• More About NSAIDs
• More About COX-2 Inhibitors
• FDA Announces Changes For All NSAIDs
• Safety of Arthritis Drugs: Weighing the Risks and Rewards
• Questions and Answers: FDA Regulatory Actions on COX-2 Inhibitors and NSAIDs